News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Kaiser Permanente signs up for Cxbladder

27 August 2014

Cxbladder User Program research agreement signed
With Kaiser Permanente Southern California

Pacific Edge Ltd has signed an agreement with Southern California Permanente Medical Group (SCPMG) to research its User Program to evaluate its bladder cancer technology Cxbladder within the clinical settings of Kaiser Permanente’s health care network.

The Kaiser Permanente User Program research project is planned to recruit approximately 2000 patients presenting with microscopic and macroscopic hematuria (blood in the urine), from the 3.7 million members of Kaiser Permanente Southern California.

The User Program research is scheduled to begin later this year with results completed in early 2015.

Pacific Edge Chief Executive David Darling says User Programs are a key part of the adoption process where customers are able to obtain data and specific experience of the benefits of using the Cxbladder technology in their own clinical settings.

Operating in eight states, Kaiser Permanente is one of America’s leading health care providers with a not-for-profit health plan. With their provision of services to 9.5 million people, Kaiser Permanente cares for a population twice the size of all of New Zealand’s District Health Boards.

“Cxbladder is targeted to provide clinicians with a means to identify patients with a high degree of surety who do not have bladder cancer. It is anticipated that significant advantages will accrue to both the patient and the health care provider from the successful integration of Cxbladder into the clinical setting. Typically less than 5 per cent of those patients who present to their clinician with microscopic hematuria (non-visible blood in urine of clinical significance) will be diagnosed with bladder cancer and approximately 12 per cent of those patients who present with visible blood in their urine. At present nearly all patients with hematuria are currently required to have an expensive clinical work-up to identify those requiring further investigation.”

User Program samples collected in Cxbladder’s proprietary urine sampling system will be sent to PEDUSA, the Company’s purpose built laboratory in Hershey, Pennsylvania for the laboratory analysis. Cxbladder results will be collated with clinical information and analysed by an independent team at SCPMG.

Pacific Edge Diagnostic USA, CEO Jackie Walker says “Kaiser Permanente is well regarded in the medical community for providing the highest standards of health care for its members through development and early adoption of industry leading technology.”

Results from the peer reviewed multi-centre Cxbladder clinical trial of 485 patients published in the prestigious Journal of Urology in the United States in September 2012 showed that Cxbladder outperformed all other benchmark technologies used in the trial and identified nearly all tumours of interest to clinicians.

Cxbladder is currently being evaluated in New Zealand for a similar clinical value proposition by Mid-Central District Health Board in Palmerston North. The commercial evaluation by Mid-Central DHB is to establish the levels of patient benefits and savings that can be achieved from the use of Cxbladder in a similar clinical setting to Kaiser Permanente by ruling out patients referred with micro-haematuria who do not have bladder cancer.

ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. Products in development and in clinical trials are accurate and simple to use genomic and proteomic tools for the earlier detection, improved characterisation and better management of gastric, bladder, colorectal cancers and melanoma. The company has recently completed and released its first product for the detection of bladder cancer, Cxbladder, and is actively marketing the product to urologists in New Zealand, Australia and the US and soon in Spain.

www.pacificedge.co.nz

ABOUT PACIFIC EDGE DIAGNOSTICS
Pacific Edge takes its exciting cancer detection tests to market through its wholly owned subsidiaries, Pacific Edge Diagnostics NZ Ltd and Pacific Edge Diagnostics USA Ltd, and selected commercial partners in Australia and Spain, Healthscope and Oryzon respectively.

www.pacificedgedx.com

ABOUT Cxbladder
Cxbladder is a proprietary, accurate molecular diagnostic test that enables the non-invasive detection of bladder cancer from a small volume of urine. It provides general practitioners and urologists with a quick, cost effective and accurate measure of the presence of the cancer, and provides urologists with the opportunity to reduce their reliance on the need for invasive tests such as cystoscopy. The recently published, Journal of Urology in September 2012, multi-centre international clinical study recruited 485 patients from Australia and New Zealand.

Results show that Cxbladder out-performed all of the benchmark technologies in the clinical trial and detected nearly all of the tumours of concern to a urologist; At a performance of 82% sensitivity and 85% specificity the test sees 100% of T1, 100% of T2, 100% of T3, 100% of Tis and 100% of upper urinary tract cancers and 97% of high grade tumours.

http://www.cxbladder.com/

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Architecture:
Ian Athfield Dies In Wellington

New Zealand Institute of Architects: It is with great sadness that we inform Members that Sir Ian Athfield, one of New Zealand's finest architects, has passed away in Wellington. More>>

ALSO:

Wellington Production: New-Look Tracy Brothers Are F.A.B.

ITV and New Zealand’s Pukeko Pictures today released an exclusive preview of the new-look Tracy brothers from this year’s hotly anticipated new series, Thunderbirds Are Go. More>>

ALSO:

Cardinal Numbers:
Pope Francis Names Archbishop From NZ Among New Cardinals

Announcing a list of bishops to be made Cardinals in February Pope Francis named Archbishop John Dew, Archbishop of Wellington, overnight from Rome. On hearing the news of the announcement, Archbishop John Dew said "This news is recognition of the Catholic Church in Aotearoa New Zealand, and the contribution it makes to the global Catholic family." More>>

ALSO:

Nomenclature: Charlotte And Oliver Top Baby Names For 2014

Charlotte and Oliver were the most popular names for newborn girls and boys in 2014... The top 100 girls’ and boys’ names make up a small proportion of the more than 12,000 unique first names registered for children born this year, says Jeff Montgomery, Registrar-General of Births, Deaths and Marriage. More>>

Werewolf: Katniss Joins The News Team

From the outset, the Hunger Games series has dwelt obsessively on the ways that media images infiltrate our public and personal lives... From that grim starting point, Mockingjay Part One takes the process a few stages further. There is very little of the film that does not involve the characters (a) being on screens (b) making propaganda footage to be screened and (c) reacting to what other characters have been doing on screens. More>>

ALSO:

Scoop Review Of Books: Ko Witi Te Kaituhituhi

Witi Ihimaera, the distinguished Māori author and the first Māori to publish a book of short stories and a novel, has adopted a new genre with his latest book. But despite its subtitle, this book is a great deal more than a memoir of childhood. More>>

Werewolf: Rescuing Paul Robeson

Would it be any harder these days, for the US government to destroy the career of a famous American entertainer and disappear them from history – purely because of their political beliefs? You would hope so. In 1940, Paul Robeson – a gifted black athlete, singer, film star, Shakespearean actor and orator – was one of the most beloved entertainers on the planet. More>>

ALSO:

"Not A Competition... A Quest": Chapman Tripp Theatre Award Winners

Big winners on the night were Equivocation (Promising Newcomer, Best Costume, Best Director and Production of the Year), Kiss the Fish (Best Music Composition, Outstanding New NZ Play and Best Supporting Actress), and Watch (Best Set, Best Sound Design and Outstanding Performance). More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news